$45M additional funding bolsters development of canine longevity drugMarch 25, 2024The latest financing round brings the total funds raised for the first FDA-approved dog lifespan extension drug to $125M
Education Center - SponsoredA New Way Forward in Canine Osteoarthritis: Targeting Pain and Inflammation at Its Sourceby • Exubrion Therapeutics The traditional approach to canine osteoarthritis (OA) has largely focused on treatments such as NSAIDs, joint supplements, stem cell, PRP, and anti-nerve growth factor (anti-NGF) injections. This raises a critical question: What if we could do more than manage symptoms? What if we could target the inflammation driving the disease?
Canine longevity drug starts clinical trialFebruary 1, 2024A whippet named Boo is the first dog dosed in the study to demonstrate healthy lifespan extension in dogs treated with LOY-002
